Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance

Not Applicable

• Conditions: Obstructive Jaundice
• Interventions: Drug: Methylene Blue

• Registration Number: NCT03406676
• Lead Sponsor: Southwest Hospital, China

Brief Summary

To explore the effects of pre-treatment with methylene blue on reduced perioperative vascular resistance in patients with obstructive jaundice.

Detailed Description

Hemodynamic characteristics of patients with obstructive jaundice are high cardiac output, low peripheral vascular resistance. The molecular basis for this feature is the increased production of NO. Methylene blue can increase peripheral resistance, the mechanism is: methylene blue is an oxidoreductase inhibitor, can inhibit the increased production of NO in the vascular endothelium, thereby increasing peripheral vascular resistance.

Study Timeline

• Study Start: 2017-08-01
• Status Verified: 2018-01
• Study First Submitted: 2018-01-04
• Study First Submitted QC: 2018-01-15
• Last Update Submitted: 2018-01-22
• Study First Posted: 2018-01-23
• Last Update Posted: 2018-01-23
• Primary Completion: 2018-10-30
• Study Completion: 2018-10-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Aged between 18-60 years;
2. American Society of Anesthesiologists（ASA） grade I~III;
3. TBIL>ULN and TBA>ULN; The patients with obstructive jaundice.

Exclusion Criteria

1. Organs dysfunction(heart,lungs and etc);
2. Mental disorders;
3. in other clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Methylene blue	Methylene Blue	2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.

Primary Outcome Measures

Name	Time	Method
Peripheral vascular resistance	through operation completion, an average of 6 hours	the dose of vasoconstrictors used to Maintain Peripheral vascular resistance in the normal range (800 \~ 1200dyns / cm5)

Trial Locations

Locations (1)

Southwest Hospital; 🇨🇳 Chongqing, Chongqing, China